

Approved for use by the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Patent Revision Act of 1952, no person is required to respond to a communication unless it contains a valid OIA authorization.

## REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

**RECEIVED**  
APR 17 2001  
File Information Unit

In re Application of <u>Cook</u>	
Application Number <u>07/566947</u>	Filed <u>8/13/90</u>
Group Art Unit	Examiner

Paper No. #17

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☐ (A) referred to in United States Patent Number 5670633 column \_\_\_\_\_
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. \_\_\_\_\_ filed \_\_\_\_\_ on page \_\_\_\_\_ of paper number \_\_\_\_\_
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. \_\_\_\_\_ filed \_\_\_\_\_ or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

\_\_\_\_\_  
\_\_\_\_\_

[Signature]  
Signature

4/17/01  
Date

\_\_\_\_\_  
Typed or printed name

<b>RECEIVED</b>
FOR PTO USE ONLY
Approved: <u>APR 17 2001</u> (Initials)
Unit: <u>R-1-4</u> File Information Unit

**Surgeon Hour Statement:** This form is estimated to take 0.2 hours to complete. Time may vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



US005670633A

## United States Patent [19]

Cook et al.

[11] Patent Number: 5,670,633

[45] Date of Patent: Sep. 23, 1997

## [54] SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION

[75] Inventors: Phillip Dan Cook, Carlsbad; Andrew Mamoro Kawasaki, Oceanside, both of Calif.

[73] Assignee: ISIS Pharmaceuticals, Inc., Carlsbad, Calif.

[21] Appl. No.: 835,932

[22] PCT Filed: Aug. 12, 1991

[86] PCT No.: PCT/US91/05720

§ 371 Date: Mar. 5, 1992

§ 102(e) Date: Mar. 5, 1992

[87] PCT Pub. No.: WO92/03568

PCT Pub. Date: Mar. 5, 1992

## Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 566,977, Aug. 13, 1990, abandoned, and Ser. No. 463,358, Jan. 11, 1990, abandoned.

[51] Int. Cl.<sup>6</sup> C07H 21/00; C07H 21/02; C07H 21/03; A01N 43/04

[52] U.S. Cl. 536/23.1; 536/23.5; 536/23.6; 536/23.7; 536/24.1; 536/24.5; 536/25.3; 536/25.31; 514/14

[58] Field of Search 536/23.1, 23.5, 536/23.6, 23.7, 24.1, 24.5, 25.3, 25.31; 514/44

## [56] References Cited

## U.S. PATENT DOCUMENTS

4,381,344	4/1983	Rideout et al.	435/87
5,013,830	5/1991	Ohtsuka et al.	536/27
5,134,066	7/1992	Rogers et al.	435/91
5,212,295	5/1993	Cook	536/26.7
5,214,135	5/1993	Srivastava et al.	536/26.7
5,466,786	11/1995	Bohr et al.	536/26.26

## FOREIGN PATENT DOCUMENTS

2017369	5/1990	Canada
0 260 032	8/1987	European Pat. Off.
0287313	10/1988	European Pat. Off.
0 399 330	5/1990	European Pat. Off.
0417999	3/1991	European Pat. Off.
3915462 A1	6/1990	Germany
41 10085 A1	10/1992	Germany
WO 90/15814	12/1990	WIPO
WO 91/06556	5/1991	WIPO
WO 91/15499	10/1991	WIPO
WO 92/07065	4/1992	WIPO

## OTHER PUBLICATIONS

Uhlmann, et al., "Antisense Oligonucleotides: A New Therapeutic Principle," *Chemical Reviews*, 1990, 558.  
 Divakar, et al., "Approaches to the Synthesis of 2'-Thio Analogues of Pyrimidine Ribosides", *J. Chem. Soc. Perkins Trans., I*, (1990), 969-974.

Divakar, et al., "Reaction Between 2,2'-Anhydro-1-β-D-arabinofuranosyluracil and Thiolate Ions", *J. Chem. Soc. Perkin Trans. I*, (1982), 1625-1628.  
 Imazawa, et al., "Nucleosides and Nucleotides, XII. Synthesis and Properties of 2'-Deoxy-2'-mercaptouridine and Its Derivatives", *Chem. Pharm. Bull.*, 23, (1975), 604-610.  
 Ryan, et al., "Synthesis of 2'-Thio-D-ribose and 2'-Thio-adenosine Derivatives", *J. Org. Chem.*, 36, No. 18, (1971), 2646-2657.  
 Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Inc., Boca Raton, FL (1989), table of contents only.  
 P. S. Miller & P.O.P. Ts'O *Anti-Cancer Drug Design*, 2:117-128 (1987).  
 Ohtsuka et al., *European Journal of Biochemistry* 139:447-450 (1984).  
 W. Guschlbauer and K. Jankowski, *Nucleic Acid Res.* 8:1421 (1980).  
 Uesugi et al., *Tetrahedron Letters* 42:4073 (1979).  
 M. Ikehara et al., *Nucleic Acids Research* 5:1877 (1978).  
 M. Ikehara et al., *Nucleic Acids Res.* 5:3315 (1978).  
 M. Ikehara et al., *Nucleic Acids Res.* 4:4249 (1977).  
 J. Hobbs et al., *Biochemistry* 11:4336 (1972).  
 H. Inoue et al., *Nucleic Acids Research* 15:6131-6148 (1987).  
 S. Shibahara et al., *Nucleic Acids Research* 17:239 (1987).  
 2:117-128 (1987).  
 Arnott and Hinkins, *Biochemical and Biophysical Research Communication*, 47:1504-1510 (1970).  
 Journal of American Chemical Society, 112:1253-1255, 1990.  
 S. Beaucage et al., *Tetrahedron Letters*, 22, 1859-1862, 1981.  
 M. Ikehara et al., *Tetrahedron* 34:1133-1138 (1978).  
 M. Ikehara *Accounts of Chemical Research*, 2:47-53 (1969).  
 Koole et al., *Journal of Organic Chemistry* 54:1657-1664 (1989).  
 R. Raganthan *Tetrahedron Letters* 15:1291-1294 (1977).  
 Codrington et al., *Journal of Organic Chemistry*, 29:558-564 (1964).  
 E. T. Jarvi, et al., *Nucleosides & Nucleotides* 8:1111-1114 (1989).  
 L. W. Hertel, et al., *Journal of Organic Chemistry* 53:2406-2409 (1988).

(List continued on next page.)

Primary Examiner—Brian Stanton  
 Attorney, Agent, or Firm—Woodcock Washburn Kurtz Mackiewicz & Norris

## [57] ABSTRACT

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least two of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of HIV, herpes virus, papillomavirus and other infections is provided.

3 Claims, No Drawings